Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Usana Health Sciences (USNA) Finished Goods (2016 - 2022)

Usana Health Sciences (USNA) has disclosed Finished Goods for 12 consecutive years, with $51.5 million as the latest value for Q3 2022.

  • Quarterly Finished Goods fell 4.14% to $51.5 million in Q3 2022 from the year-ago period, while the trailing twelve-month figure was $51.5 million through Jul 2022, down 4.14% year-over-year, with the annual reading at $58.5 million for FY2022, 12.54% up from the prior year.
  • Finished Goods for Q3 2022 was $51.5 million at Usana Health Sciences, down from $57.3 million in the prior quarter.
  • The five-year high for Finished Goods was $58.5 million in Q1 2022, with the low at $36.6 million in Q1 2020.
  • Average Finished Goods over 5 years is $47.8 million, with a median of $48.7 million recorded in 2018.
  • The sharpest move saw Finished Goods skyrocketed 42.23% in 2018, then tumbled 30.13% in 2020.
  • Over 5 years, Finished Goods stood at $48.0 million in 2018, then fell by 14.69% to $40.9 million in 2019, then grew by 15.12% to $47.1 million in 2020, then increased by 16.78% to $55.0 million in 2021, then decreased by 6.3% to $51.5 million in 2022.
  • According to Business Quant data, Finished Goods over the past three periods came in at $51.5 million, $57.3 million, and $58.5 million for Q3 2022, Q2 2022, and Q1 2022 respectively.